Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer

NCT00047801 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-small-cell Lung

Interventions

DRUG: TLK286 in combination with docetaxel

Sponsor

Telik